Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2550)	1/26/2010 12:00:09 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ALKS was up 15.49% at its intraday H after opening with a good UG.<g> The stock still is up 9.65% with volume of >1,920,000 already close to 2x its ADV bigcharts.marketwatch.com The stock is also benefiting from the FDA's approval of NVO's Victoza for BID injections on patients of type2 DM. The further cost for Exenatide development supposedly will be carried by LLY. <g> ALKS has a good amount of cash and several other products on its pipeline. The ACTAY is $10.29, but it seems that with some good news it could get to test the Aug2008 H at $17.05 <g> bigcharts.marketwatch.com Bernard